{'fraction_non_alphanumeric': 0.03285870755750274, 'fraction_numerical': 0.01095290251916758, 'mean_word_length': 5.436619718309859, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Acetylcholinesterase inhibitors based on carbamic acid quinolin-6-yl esters

The application claims two related kinds of carbamic acid esters, namely the ones of quinolin-6-ol and 1-substituted 1,2,3,4-tetrahydroquinolin-6-ols as novel inhibitors of acetylcholinesterase. Hexyl-, heptyl- and substituted phenyl-carbamic acids were prepared, in which the 1-position of the tetrahydro-quinolinol was either unsubstituted or bore a methyl or benzyl group. Some data concerning their in vitro inhibition are presented, as is the testing of a set of compounds in an in vivo assay (amelioration of scopolamine-induced cognitive impairment in a passive avoidance test), in which the compounds tested showed cognitive improvements comparable to standard Alzheimer's disease drugs. These compounds are among the few patents with novel templates for acetylcholinesterase-inhibiting carbamates described in the past 3 years.